Janus kinase inhibitors and risk of internal malignancy in dermatomyositis

J Dermatolog Treat. 2022 Sep;33(6):2881-2882. doi: 10.1080/09546634.2022.2089323. Epub 2022 Jun 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • Dermatomyositis* / drug therapy
  • Humans
  • Janus Kinase Inhibitors* / adverse effects
  • Neoplasms* / etiology
  • Pyrazoles
  • Pyrimidines

Substances

  • Janus Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines